Literature DB >> 11283046

Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay.

N Désiré1, A Dehée, V Schneider, C Jacomet, C Goujon, P M Girard, W Rozenbaum, J C Nicolas.   

Abstract

Proviral human immunodeficiency virus type 1 (HIV-1) DNA could be a useful marker for exploring viral reservoirs and monitoring antiretroviral treatment, particularly when HIV-1 RNA is undetectable in plasma. A new technique was developed to quantify proviral HIV-1 using a TaqMan real-time PCR assay. One copy of proviral HIV-1 DNA could be detected with 100% sensitivity for five copies and the assay had a range of 6 log(10). Reproducibility was evaluated in intra- and interassays using independent extractions of the 8E5 cell line harboring the HIV-1 proviral genome (coefficients of variation [CV], 13 and 27%, respectively) and peripheral blood mononuclear cells (PBMC) from a patient with a mean proviral load of 26 copies per 10(6) PBMC (CV, 46 and 56%, respectively). The median PBMC proviral load of 21 patients, measured in a cross-sectional study, was determined to be 215 copies per 10(6) PBMC (range, <10 to 8,381). In a longitudinal study, the proviral load of 15 out of 16 patients with primary infection fell significantly during 1 year of antiretroviral therapy (P = 0.004). In the remaining patient, proviral HIV-1 DNA was detectable but not quantifiable due to a point mutation at the 5' end of the TaqMan probe. No correlation was observed between proviral load and levels of CD4(+) cells or HIV-1 RNA in plasma. TaqMan PCR is sensitive and adaptable to a large series of samples. The full interest of monitoring proviral HIV-1 DNA can now be ascertained by its application to the routine monitoring of patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283046      PMCID: PMC87929          DOI: 10.1128/JCM.39.4.1303-1310.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  38 in total

1.  Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.

Authors:  A Ibáñez; T Puig; J Elias; B Clotet; L Ruiz; M A Martínez
Journal:  AIDS       Date:  1999-06-18       Impact factor: 4.177

2.  Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.

Authors:  J J Zaunders; P H Cunningham; A D Kelleher; G R Kaufmann; A B Jaramillo; R Wright; D Smith; P Grey; J Vizzard; A Carr; D A Cooper
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

3.  Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.

Authors:  P M Girard; V Schneider; A Dehée; P Mariot; C Jacomet; N Delphin; F Damond; G Carcelain; B Autran; A G Saimot; J C Nicolas; W Rozenbaum
Journal:  AIDS       Date:  2001-01-26       Impact factor: 4.177

4.  PCR-Based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells.

Authors:  C Christopherson; Y Kidane; B Conway; J Krowka; H Sheppard; S Kwok
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

5.  Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI).

Authors:  S Aoki; R Yarchoan; R V Thomas; J M Pluda; K Marczyk; S Broder; H Mitsuya
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

6.  Quantitation of human immunodeficiency virus provirus and circulating virus: relationship with immunologic parameters.

Authors:  S Yerly; E Chamot; B Hirschel; L H Perrin
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

7.  Comparative assessment of quantitative HIV viraemia assays.

Authors:  C Rouzioux; J Puel; H Agut; F Brun-Vézinet; F Ferchal; C Tamalet; P Descamps; H Fleury
Journal:  AIDS       Date:  1992-04       Impact factor: 4.177

8.  High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.

Authors:  S J Clark; M S Saag; W D Decker; S Campbell-Hill; J L Roberson; P J Veldkamp; J C Kappes; B H Hahn; G M Shaw
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

9.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection.

Authors:  E S Daar; T Moudgil; R D Meyer; D D Ho
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

10.  Decreases in unintegrated HIV DNA are associated with antiretroviral therapy in AIDS patients.

Authors:  R E Dickover; R M Donovan; E Goldstein; S H Cohen; V Bolton; R G Huth; G Z Liu; J R Carlson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992
View more
  51 in total

1.  Quantification of human immunodeficiency virus type 1 proviral DNA by the TaqMan real-time PCR assay.

Authors:  Zhibing Yun; Eva Fredriksson; Anders Sönnerborg
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

2.  HIV-1 proviral DNA loads (as determined by quantitative PCR) in patients subjected to structured treatment interruption after antiretroviral therapy failure.

Authors:  Shirley V Komninakis; Domingos E M Santos; Carlos Santos; Márcia P R Oliveros; Sabri Sanabani; Ricardo S Diaz
Journal:  J Clin Microbiol       Date:  2012-03-14       Impact factor: 5.948

3.  Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes.

Authors:  Peilin Li; Theodore Ruel; Katsuya Fujimoto; Hiroyu Hatano; Steven Yukl; Leigh Anne Eller; Teri Liegler; Moses Kamya; Anne Gassasira; Grant Dorsey; Philip J Rosenthal; Diane V Havlir; Joseph K Wong
Journal:  J Virol Methods       Date:  2010-09-21       Impact factor: 2.014

4.  Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro.

Authors:  Vanessa Roulet; Anne-Pascale Satie; Annick Ruffault; Anna Le Tortorec; Hélène Denis; Odile Guist'hau; Jean-Jacques Patard; Nathalie Rioux-Leclerq; Janine Gicquel; Bernard Jégou; Nathalie Dejucq-Rainsford
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

Review 5.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

6.  Fluorogenic LUX primer for quantitation of HIV-1 by real-time RT-PCR.

Authors:  Natela Rekhviashvili; Gwynneth Stevens; Lesley Scott; Wendy Stevens
Journal:  Mol Biotechnol       Date:  2006-02       Impact factor: 2.695

7.  Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes.

Authors:  Sa Deepak; Kr Kottapalli; R Rakwal; G Oros; Ks Rangappa; H Iwahashi; Y Masuo; Gk Agrawal
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

8.  Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.

Authors:  Yuyang Tang; Francois Villinger; Silvija I Staprans; Rama Rao Amara; James M Smith; James G Herndon; Harriet L Robinson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load.

Authors:  Leondios G Kostrikis; Giota Touloumi; Rose Karanicolas; Nikos Pantazis; Cleo Anastassopoulou; Anastasia Karafoulidou; James J Goedert; Angelos Hatzakis
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Early HIV-1 diagnosis using in-house real-time PCR amplification on dried blood spots for infants in remote and resource-limited settings.

Authors:  Nicole Ngo-Giang-Huong; Woottichai Khamduang; Baptiste Leurent; Intira Collins; Issaren Nantasen; Pranee Leechanachai; Wasna Sirirungsi; Aram Limtrakul; Tasana Leusaree; Anne Marie Comeau; Marc Lallemant; Gonzague Jourdain
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.